Table 2 Demographic data, clinical manifestations and treatments in patients with scrotal involvement at first episode compared to those without this condition in 149 IgA vasculitis patients
From: Characterization of scrotal involvement in children and adolescents with IgA vasculitis
| Variables at diagnosis, n (%) |
With scrotal involvement (n = 27) |
Without scrotal involvement (n = 122) |
|---|---|---|
| Demographic data | ||
| Age at diagnosis, years | 4.0 (2.0–12.0) | 6.0 (1.3–13.0) |
| Body mass index, kg/m2, n = 139 | 16.4 (13.2–20.3) | 16 (12.5–32.7) |
| Clinical/laboratorial involvements | ||
| Persistent purpura/petechiae, n = 146 | 6/27 (22) | 25/119 (21) |
| Recurrent purpura/petechiae | 7 (26) | 20 (16) |
| Purpura/petechiae duration, days, n = 140 | 18.5 (5–60) | 14 (1–120) |
| Arthritis/arthralgia | 21 (78) | 95 (77) |
| Recurrent arthritis/arthralgia | 1 (4) | 6 (5) |
| Arthritis/arthralgia duration, days, n = 100 | 4 (2–13) | 6 (1–113) |
| Abdominal pain | 20 (74) | 73 (59) |
| Recurrent abdominal pain, n = 149 | 3/26 (12) | 16/123 (13) |
| Severe abdominal pain, n = 92 | 7/20 (35) | 26/72 (36) |
| Abdominal pain duration, days, n = 83 | 4.5 (1–40) | 5 (1–60) |
| Gastrointestinal bleeding, n = 149 | 6/27 (22) | 23/122 (19) |
| Bowel intussusception | 0 (0) | 1 (0.8) |
| Nephritis, n = 147 | 10/27 (37) | 56/120 (47) |
| Arterial hypertension, n = 122 | 4/22 (18) | 16/100 (16) |
| Nephrotic syndrome, n = 147 | 0/26 (0) | 3/121 (3) |
| Acute kidney injury, n = 145 | 0/27 (0) | 2/118 (2) |
| Leukocyturia, n = 146 | 0/27 (0) | 14/119 (12) |
| Urinary casts, n = 146 | 2/27 (7) | 13/119 (11) |
| Hematuria, n = 146 | 7/27 (26) | 39/119 (33) |
| Proteinuria, n = 108 | 5/17 (29) | 34/91 (37) |
| Neuropsychiatric involvement | 0 (0) | 1 (1) |
| Increased serum IgA, n = 76 | 2/11 (18) | 37/65 (57)* |
| Treatments | ||
| Prednisone | 25 (93) | 60 (49)* |
| Intravenous metilprednisolone | 0 (0) | 1 (1) |
| Prednisone dose, mg/kg/day, n = 72 | 2 (0.5–2) | 1 (0.2–30) |
| Glucorticosteroid duration, days, n = 76 | 47.5 (7–140) | 37.5 (1–240) |
| Ranitidine, n = 149 | 17/27 (63) | 37/122 (30)* |
| Ranitidine duration, days, n = 57 | 35 (2–90) | 60 (5–425) |
| Immunosuppressive agents | 0 (0) | 0 (0) |
| IVIG | 1 (4) | 1 (1) |